Title of article
Clinical Challenges with Talimogene Laherparepvec: CuredLymph Nodes Masquerading as Active Melanoma
Author/Authors
Milhem, Mohammed Department of Hematology - Oncology and Blood and Marrow Transplantation - University of Iowa Hospitals and Clinics - Iowa City - IA 52242, USA , Swami, Umang Department of Hematology - Oncology and Blood and Marrow Transplantation - University of Iowa Hospitals and Clinics - Iowa City - IA 52242, USA , Zakharia, Yousef Department of Hematology - Oncology and Blood and Marrow Transplantation - University of Iowa Hospitals and Clinics - Iowa City - IA 52242, USA , Swick, Brian Department of Dermatology and Pathology - University of Iowa Hospitals and Clinics - 200 Hawkins Dr - Iowa City, USA
Pages
6
From page
1
To page
6
Abstract
Talimogene laherparepvec is a novel, genetically engineered, oncolytic herpes virus approved for local treatment of unresectablecutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. It is administered as anintralesional injection. However, if the lesion continues to persist, it presents with a clinical challenge as when to stop treatment.Herein, we present two cases from our institution wherein the disease appeared to be persistent radiologically; however, onpathological excision, there was no evidence of disease and patients continue to be in durable remission after stopping treatment.
Keywords
Clinical Challenges , Talimogene Laherparepvec , CuredLymph Nodes Masquerading , Active Melanoma
Journal title
Case Reports in Oncological Medicine
Serial Year
2019
Record number
2610584
Link To Document